Metasens 500 Tablet SR contains Metformin 500 mg, an oral antihyperglycemic agent belonging to the biguanide class, primarily indicated for the management of type 2 diabetes mellitus. Metformin acts by decreasing hepatic glucose production, decreasing intestinal absorption of glucose, and improving insulin sensitivity by increasing peripheral glucose uptake and utilization. This sustained-release formulation ensures a gradual release of the active ingredient, enhancing gastrointestinal tolerability and improving patient compliance through reduced dosing frequency. Metasens 500 Tablet SR is prescribed as monotherapy or in combination with other antidiabetic agents, including insulin, when diet and exercise alone do not achieve adequate glycemic control. It is particularly beneficial in overweight or obese patients due to its weight-neutral or weight-reducing effects. Common adverse effects may include gastrointestinal disturbances such as nausea, vomiting, diarrhea, and abdominal discomfort, which tend to diminish with continued use. Metasens 500 Tablet SR is contraindicated in patients with renal impairment, metabolic acidosis, or hypersensitivity to Metformin. Regular monitoring of renal function and blood glucose levels is recommended during therapy. Proper adherence to prescribed dosage and lifestyle modifications enhances therapeutic outcomes and reduces the risk of diabetes-related complications.